CERO THERAPEUTICS HOLDINGS, INC. (CERO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US71902K4022
CERO THERAPEUTICS HOLDINGS, INC. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -19.92 m USD |
| Net income | -19.92 m USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
More stocks
- Paion AG (PA8.F)
- Goliath Film & Media Holdings (GFMH)
- 60 DEGREES PHARMACEUTICALS, INC. (SXTP)
- Transportation & Logistics Systems, Inc. (TLSS)
- Seoul Food Ind Co Ltd (004415.KS)
- Purebase Corp (PUBC)
- Matinas BioPharma Holdings, Inc. (MTNB)
- Stardust Power Inc. (SDST)
- Hypha Labs, Inc. (FUNI)
- Blue Line Protection Group, Inc. (BLPG)
- Stemtech Corp (STEK)
- Fyntechnical Innovations Inc (FYNN)
Not investment advice. All data without warranty, price as of 18.11.2026. Details in the risk notice.